The complex pathological cascades leading to both Alzheimer's disease (AD) and Parkinson's disease (PD) involve, at various points, inflammation. Since inflammation is a treatable symptom, understanding how and when it impacts the brain, and where specifically in the brain, would offer important guidance in the development of new treatments, sorely needed in both diseases.
Microglia play an important anti-inflammatory role, and produce a substance, mitochondrial translocator protein (TSPO), whose presence can be used as a marker of regional inflammation. GE180 is a newly developed PET ligand which binds to TSPO and hence can be used in imaging studies to analyze regional inflammation in living patients. In prior studies it has shown regional specificity in multiple sclerosis and brain injury. In the current study, the investigators will be using GE180 to analyze regional and global inflammation in the brains of patients with AD and PD at a single time point.
The results of the current study will provide enriched understanding of inflammation in these conditions, and potentially provide preliminary data to inform design of future interventional trials.

开始日期2018-12-13

申办/合作机构

The Cleveland Clinic Foundation

JPRN-UMIN000030084

/ Completed临床1/2期IIT

Practical evaluation of PET studies with [18F]-GE180, [18F]-FDOPA and [18F]-FLT for a future clinical trial of iPSC-based cell therapy in Parkinson's disease - Practical evaluation of PET studies with three tracers for iPSC derived-neural transplantation

开始日期2017-12-01

申办/合作机构

Kyoto University

100 项与 Flutriciclamide (18F) 相关的临床结果

登录后查看更多信息

100 项与 Flutriciclamide (18F) 相关的转化医学

登录后查看更多信息

100 项与 Flutriciclamide (18F) 相关的专利（医药）

登录后查看更多信息

项与 Flutriciclamide (18F) 相关的文献（医药）

2024-07-01·European Journal of Nuclear Medicine and Molecular Imaging

Enhancing predictability of IDH mutation status in glioma patients at initial diagnosis: a comparative analysis of radiomics from MRI, [18F]FET PET, and TSPO PET

Article

作者: Holzgreve, A ; Ruf, V C ; Riemenschneider, M J ; Ziegler, S ; Wiestler, B ; Kaiser, Lena ; Bartos, L M ; Zounek, A J ; Herms, J ; Böning, G ; Stöcklein, S ; Albert, N L ; Thon, N ; Zatcepin, A ; Bartenstein, P ; von Baumgarten, L ; Rupprecht, R ; Brendel, M ; Bollenbacher, A ; Quach, S ; Tonn, J C

Abstract:

Purpose:

According to the World Health Organization classification for tumors of the central nervous system, mutation status of the isocitrate dehydrogenase (IDH) genes has become a major diagnostic discriminator for gliomas. Therefore, imaging-based prediction of IDH mutation status is of high interest for individual patient management. We compared and evaluated the diagnostic value of radiomics derived from dual positron emission tomography (PET) and magnetic resonance imaging (MRI) data to predict the IDH mutation status non-invasively.

Methods:

Eighty-seven glioma patients at initial diagnosis who underwent PET targeting the translocator protein (TSPO) using [18F]GE-180, dynamic amino acid PET using [18F]FET, and T1-/T2-weighted MRI scans were examined. In addition to calculating tumor-to-background ratio (TBR) images for all modalities, parametric images quantifying dynamic [18F]FET PET information were generated. Radiomic features were extracted from TBR and parametric images. The area under the receiver operating characteristic curve (AUC) was employed to assess the performance of logistic regression (LR) classifiers. To report robust estimates, nested cross-validation with five folds and 50 repeats was applied.

Results:

TBRGE-180 features extracted from TSPO-positive volumes had the highest predictive power among TBR images (AUC 0.88, with age as co-factor 0.94). Dynamic [18F]FET PET reached a similarly high performance (0.94, with age 0.96). The highest LR coefficients in multimodal analyses included TBRGE-180 features, parameters from kinetic and early static [18F]FET PET images, age, and the features from TBRT2 images such as the kurtosis (0.97).

Conclusion:

The findings suggest that incorporating TBRGE-180 features along with kinetic information from dynamic [18F]FET PET, kurtosis from TBRT2, and age can yield very high predictability of IDH mutation status, thus potentially improving early patient management.

2022-10-01·JOURNAL OF NUCLEAR MEDICINE1区 · 医学

Tracking Innate Immune Activation in a Mouse Model of Parkinson’s Disease Using TREM1 and TSPO PET Tracers

1区 · 医学

Article

作者: Bonham, T Adam ; Lucot, Katherine L ; Azevedo, E Carmen ; Graves, Edward E ; James, Michelle L ; Stevens, Marc Y ; Jackson, Isaac M ; Webber, Ebony D ; Klockow, Jessica L ; Chaney, Aisling M ; Montine, Thomas J ; Jain, Poorva ; Carlson, Mackenzie L

Parkinson's disease (PD) is associated with aberrant innate immune responses, including microglial activation and infiltration of peripheral myeloid cells into the central nervous system (CNS). Methods to investigate innate immune activation in PD are limited and have not yet elucidated key interactions between neuroinflammation and peripheral inflammation. Translocator protein 18 kDa (TSPO) PET is a widely evaluated imaging approach for studying activated microglia and peripheral myeloid lineage cells in vivo but has yet to be fully explored in PD. Here, we investigate the utility of TSPO PET in addition to PET imaging of triggering receptor expressed on myeloid cells 1 (TREM1)-a novel biomarker of proinflammatory innate immune cells-for detecting innate immune responses in the 6-hydroxydopamine mouse model of dopaminergic neuron degeneration. Methods: C57/BL6J and TREM1 knockout mice were stereotactically injected with 6-hydroxydopamine in the left striatum; control mice were injected with saline. At day 7 or 14 after surgery, mice were administered ¹⁸F-GE-180, ⁶⁴Cu-TREM1 monoclonal antibody (mAb), or ⁶⁴Cu-isotype control mAb and imaged by PET/CT. Ex vivo autoradiography was performed to obtain high-resolution images of tracer binding within the brain. Immunohistochemistry was conducted to verify myeloid cell activation and dopaminergic cell death, and quantitative polymerase chain reaction and flow cytometry were completed to assess levels of target in the brain. Results: PET/CT images of both tracers showed elevated signal within the striatum of 6-hydroxydopamine-injected mice compared with those injected with saline. Autoradiography afforded higher-resolution brain images and revealed significant TSPO and TREM1 tracer binding within the ipsilateral striatum of 6-hydroxydopamine mice compared with saline mice at both 7 and 14 d after toxin. Interestingly, ¹⁸F-GE-180 enabled detection of inflammation in the brain and peripheral tissues (blood and spleen) of 6-hydroxydopamine mice, whereas ⁶⁴Cu-TREM1 mAb appeared to be more sensitive and specific for detecting neuroinflammation, in particular infiltrating myeloid cells, in these mice, as demonstrated by flow cytometry findings and higher tracer binding signal-to-background ratios in brain. Conclusion: TSPO and TREM1 PET tracers are promising tools for investigating different cell types involved in innate immune activation in the context of dopaminergic neurodegeneration, thus warranting further investigation in other PD rodent models and human postmortem tissue to assess their clinical potential.

2020-12-01·Journal of neuroinflammation1区 · 医学

Glial activation is moderated by sex in response to amyloidosis but not to tau pathology in mouse models of neurodegenerative diseases

1区 · 医学

ArticleOA

作者: Franzmeier, Nicolai ; Ruch-Rubinstein, Francois ; Luque, Jose Medina ; von Ungern-Sternberg, Barbara ; Lindner, Simon ; Cumming, Paul ; Ewers, Michael ; Höglinger, Günter U ; Sacher, Christian ; Brendel, Matthias ; Eckenweber, Florian ; Rominger, Axel ; Blume, Tanja ; Herms, Jochen ; Bartenstein, Peter ; Biechele, Gloria ; Gildehaus, Franz-Josef ; Beyer, Leonie

Abstract:

Background:

In vivo assessment of neuroinflammation by 18-kDa translocator protein positron-emission-tomography (TSPO-PET) ligands receives growing interest in preclinical and clinical research of neurodegenerative disorders. Higher TSPO-PET binding as a surrogate for microglial activation in females has been reported for cognitively normal humans, but such effects have not yet been evaluated in rodent models of neurodegeneration and their controls. Thus, we aimed to investigate the impact of sex on microglial activation in amyloid and tau mouse models and wild-type controls.

Methods:

TSPO-PET (18F-GE-180) data of C57Bl/6 (wild-type), AppNL-G-F (β-amyloid model), and P301S (tau model) mice was assessed longitudinally between 2 and 12 months of age. The AppNL-G-F group also underwent longitudinal β-amyloid-PET imaging (Aβ-PET; 18F-florbetaben). PET results were confirmed and validated by immunohistochemical investigation of microglial (Iba-1, CD68), astrocytic (GFAP), and tau (AT8) markers. Findings in cerebral cortex were compared by sex using linear mixed models for PET data and analysis of variance for immunohistochemistry.

Results:

Wild-type mice showed an increased TSPO-PET signal over time (female +23%, male +4%), with a significant sex × age interaction (T = − 4.171, p < 0.001). The Aβ model AppNL-G-F mice also showed a significant sex × age interaction (T = − 2.953, p = 0.0048), where cortical TSPO-PET values increased by 31% in female AppNL-G-F mice, versus only 6% in the male mice group from 2.5 to 10 months of age. Immunohistochemistry for the microglial markers Iba-1 and CD68 confirmed the TSPO-PET findings in male and female mice aged 10 months. Aβ-PET in the same AppNL-G-F mice indicated no significant sex × age interaction (T = 0.425, p = 0.673). The P301S tau model showed strong cortical increases of TSPO-PET from 2 to 8.5 months of age (female + 32%, male + 36%), without any significant sex × age interaction (T = − 0.671, p = 0.504), and no sex differences in Iba-1, CD68, or AT8 immunohistochemistry.

Conclusion:

Female mice indicate sex-dependent microglia activation in aging and in response to amyloidosis but not in response to tau pathology. This calls for consideration of sex difference in TSPO-PET studies of microglial activation in mouse models of neurodegeneration and by extension in human studies.

项与 Flutriciclamide (18F) 相关的新闻（医药）

2022-08-01

·GlobeNewswire-Health Care

Ashvattha Therapeutics Announces Preclinical Data at the 2022 Alzheimer’s Association International Conference (AAIC) Demonstrating its Hydroxyl Dendrimer-Based Imaging Agent [18F]OP-801 Can Detect Early-Stage Neuroinflammation with a Higher Sensitivity Than TSPO-PET

Data highlights [18F]OP-801’s differentiated imaging profile as a promising tracer for visualizing the progression of neuroinflammationREDWOOD CITY, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer (HD)-based PET tracer, [18F]OP-801, can detect neuroinflammation via activated microglia and macrophages with higher sensitivity than translocator protein 18 kDa [TSPO]-PET, using [18F]GE180, an established and validated PET imaging approach, in a mouse model of Alzheimer’s Disease. The data were presented by Mackenzie Carlson, a scientific collaborator at Stanford University, in a poster titled, “Novel hydroxyl dendrimer-based PET tracer [18F]OP-801 detects early-stage neuroinflammation in 5xFAD mouse model with higher sensitivity than TSPO-PET,” at the 2022 Alzheimer’s Association International Conference (AAIC) taking place at the San Diego Convention Center in San Diego, CA, and online, July 31 – August 4, 2022. “We are encouraged by the data as it supports the potential of our HD-based PET tracer, [18F]OP-801, to be an effective imaging agent for detecting early-stage neuroinflammation, a hallmark of neurodegenerative diseases including Alzheimer’s,” said Jeffrey Cleland, Ph.D., Chairman & CEO of Ashvattha Therapeutics. “The data also build on previous studies and validates our hydroxyl dendrimer’s ability to cross the blood-brain barrier and be selectively taken up by reactive inflammatory cells. By measuring the extent of [18F]OP-801 uptake in the brain, we will be able select patients with HD uptake based on PET signal. These patients will then be treated with the same HD chemically linked to a drug to treat the disease. Ultimately, this means that we will be able to provide physicians insight on how much drug will get to the diseased part of the patient’s brain before the treatment. No other non-invasive approach can achieve this key de-risking of neurological therapy.” Key highlights from the presentation include: At 3.75 months of age, [18F]OP-801 yielded a 3-fold higher PET signal in diseased mice compared to healthy mice demonstrating the superior selectivity of the tracer towards activated macrophages and microglia.No significant differences were observed between healthy and diseased mice in PET images using [18F]GE180.Images from brains of diseased mice at 5 months of age showed significantly greater uptake of [18F]OP-801 when compared to healthy mice in the same age group across the entirety of the brain and especially in regions commonly associated with Alzheimer's disease Chronic activation of macrophages and microglia plays a critical role in the onset and progression of many neurological diseases. While PET imaging has the potential to non-invasively visualize and quantify innate immune responses in vivo, most available PET tracers are not specific for macrophages/microglia. To address this need, Ashvattha is developing a HD-based PET tracer, [18F]OP-801, as a companion biomarker to pair with its HD therapeutics to treat neuroinflammation. About [18F]OP-801 [18F]OP-801 is a hydroxyl dendrimer-based neuroimaging agent being developed as a companion biomarker and a pharmacodynamic tool for therapeutics to treat neuroinflammation due to neurodegenerative diseases including Alzheimer’s and amyotrophic lateral sclerosis (ALS). This imaging agent was designed to cross the blood-brain barrier — a highly selective membrane that prevents most molecules from reaching the brain and spinal cord — in the presence of inflammation and to enter active microglial cells so they can be seen on images. [18F]-OP801 has been shown to be selectively (>95%) taken up by reactive macrophages/microglia.1 [18F]OP-801 shows promise for visualizing the progression of neuroinflammation with high specificity and sensitivity, warranting clinical investigation. A Phase 1/2 clinical trial of [18F]OP-801 is currently underway in healthy volunteers and ALS patients. About Ashvattha Therapeutics Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammatory diseases and neuro-oncology. The therapies are based on hydroxyl dendrimers (HDs), a targeted platform technology exclusively licensed from our founders, Kannan Rangaramanujam and Sujatha Kannan at Johns Hopkins University. HDs chemically conjugated to disease-modifying drugs create novel proprietary HD therapeutics (HDTs) selectively targeting reactive inflammatory cells in disease tissue with localized sustained effects. Ashvattha has initiated multiple programs with HDTs focused on neurology, ocular neovascular disease including neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME), and hyperinflammation in diseases. For more information, visit: www.avttx.com. Media Contact Jordyn Temperato LifeSci Communicationsjtemperato@lifescicomms.com 1 Henningfield, C.M., Cleland, J.L., Sharma, R., Green, K.N.Selective targeting of plaque-associated microglia through systemic dendrimer administration in an Alzheimer’s disease model. Alzheimer's & Dementia. 2020; Volume 16. Issue S2. https://doi.org/10.1002/alz.040661

2022-08-01

·BioSpace

Ashvattha Therapeutics Announces Preclinical Data at the 2022 AAIC Demonstrating its Hydroxyl Dendrimer-Based Imaging Agent [18F]OP-801 Can Detect Early-Stage Neuroinflammation with a Higher Sensitivity Than TSPO-PET

Data highlights [18F]OP-801’s differentiated imaging pro a promising tracer for visualizing the progression of neuroinflammation REDWOOD CITY, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer (HD)-based PET tracer, [18F]OP-801, can detect neuroinflammation via activated microglia and macrophages with higher sensitivity than translocator protein 18 kDa [TSPO]-PET, using [18F]GE180, an established and validated PET imaging approach, in a mouse model of Alzheimer’s Disease. The data were presented by Mackenzie Carlson, a scientific collaborator at Stanford University, in a poster titled, “Novel hydroxyl dendrimer-based PET tracer [18F]OP-801 detects early-stage neuroinflammation in 5xFAD mouse model with higher sensitivity than TSPO-PET,” at the 2022 Alzheimer’s Association International Conference (AAIC) taking place at the San Diego Convention Center in San Diego, CA, and online, July 31 – August 4, 2022. “We are encouraged by the data as it supports the potential of our HD-based PET tracer, [18F]OP-801, to be an effective imaging agent for detecting early-stage neuroinflammation, a hallmark of neurodegenerative diseases including Alzheimer’s,” said Jeffrey Cleland, Ph.D., Chairman & CEO of Ashvattha Therapeutics. “The data also build on previous studies and validates our hydroxyl dendrimer’s ability to cross the blood-brain barrier and be selectively taken up by reactive inflammatory cells. By measuring the extent of [18F]OP-801 uptake in the brain, we will be able select patients with HD uptake based on PET signal. These patients will then be treated with the same HD chemically linked to a drug to treat the disease. Ultimately, this means that we will be able to provide physicians insight on how much drug will get to the diseased part of the patient’s brain before the treatment. No other non-invasive approach can achieve this key de-risking of neurological therapy.” Key highlights from the presentation include: At 3.75 months of age, [18F]OP-801 yielded a 3-fold higher PET signal in diseased mice compared to healthy mice demonstrating the superior selectivity of the tracer towards activated macrophages and microglia. No significant differences were observed between healthy and diseased mice in PET images using [18F]GE180. Images from brains of diseased mice at 5 months of age showed significantly greater uptake of [18F]OP-801 when compared to healthy mice in the same age group across the entirety of the brain and especially in regions commonly associated with Alzheimer's disease Chronic activation of macrophages and microglia plays a critical role in the onset and progression of many neurological diseases. While PET imaging has the potential to non-invasively visualize and quantify innate immune responses in vivo, most available PET tracers are not specific for macrophages/microglia. To address this need, Ashvattha is developing a HD-based PET tracer, [18F]OP-801, as a companion biomarker to pair with its HD therapeutics to treat neuroinflammation. About [18F]OP-801 [18F]OP-801 is a hydroxyl dendrimer-based neuroimaging agent being developed as a companion biomarker and a pharmacodynamic tool for therapeutics to treat neuroinflammation due to neurodegenerative diseases including Alzheimer’s and amyotrophic lateral sclerosis (ALS). This imaging agent was designed to cross the blood-brain barrier — a highly selective membrane that prevents most molecules from reaching the brain and spinal cord — in the presence of inflammation and to enter active microglial cells so they can be seen on images. [18F]-OP801 has been shown to be selectively (>95%) taken up by reactive macrophages/microglia.1 [18F]OP-801 shows promise for visualizing the progression of neuroinflammation with high specificity and sensitivity, warranting clinical investigation. A Phase 1/2 clinical trial of [18F]OP-801 is currently underway in healthy volunteers and ALS patients. About Ashvattha Therapeutics Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammatory diseases and neuro-oncology. The therapies are based on hydroxyl dendrimers (HDs), a targeted platform technology exclusively licensed from our founders, Kannan Rangaramanujam and Sujatha Kannan at Johns Hopkins University. HDs chemically conjugated to disease-modifying drugs create novel proprietary HD therapeutics (HDTs) selectively targeting reactive inflammatory cells in disease tissue with localized sustained effects. Ashvattha has initiated multiple programs with HDTs focused on neurology, ocular neovascular disease including neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME), and hyperinflammation in diseases. For more information, visit: . Media Contact Jordyn Temperato LifeSci Communications jtemperato@lifescicomms.com 1 Henningfield, C.M., Cleland, J.L., Sharma, R., Green, K.N.Selective targeting of plaque-associated microglia through systemic dendrimer administration in an Alzheimer’s disease model. Alzheimer's & Dementia. 2020; Volume 16. Issue S2.

2022-07-18

·GlobeNewswire-Health Care

Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on Hydroxyl Dendrimer-Based PET Tracer [18F]OP-801 at the 2022 Alzheimer's Association International Conference (AAIC)

– Scientific collaborators at Stanford University will present preclinical data on the sensitivity of [18F]OP-801 in comparison to TSPO-PET for detecting early-stage neuroinflammation – REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data on the sensitivity of its hydroxyl dendrimer-based PET tracer, [18F]OP-801, in comparison to translocator protein 18 kDa [TSPO]-PET, using [18F]GE180 (TSPO-PET), an established PET imaging approach for the detection of neuroinflammation, in a mouse model of Alzheimer’s Disease. The data will be presented by scientific collaborators at Stanford University in a poster at the 2022 Alzheimer's Association International Conference (AAIC) taking place at the San Diego Convention Center in San Diego, CA, and online, July 31 – August 4, 2022. Poster presentation details can be found below: Title: Novel hydroxyl dendrimer-based PET tracer [18F]OP-801 detects early-stage neuroinflammation in 5xFAD mouse model with higher sensitivity than TSPO-PETPoster Number: 60700Poster Session: P1-07 Biomarkers: NeuroimagingPresenter: Mackenzie Carlson, NSF Graduate Research Fellow at Stanford University School of Medicine Date/Time: Sunday, July 31, 2022, 9:15 a.m. – 4:45 p.m. PT Location: San Diego Convention Center Exhibit Hall About [18F]OP-801[18F]OP-801 is a hydroxyl dendrimer-based neuroimaging agent being developed as a companion biomarker and a pharmacodynamic tool for therapeutics to treat neuroinflammation due to neurodegenerative diseases including Alzheimer’s and amyotrophic lateral sclerosis (ALS). This imaging agent was designed to cross the blood-brain barrier — a highly selective membrane that prevents most molecules from reaching the brain and spinal cord — in the presence of inflammation and to enter active microglial cells so they can be seen on images. [18F]OP-801 has been shown to be selectively (>95%) taken up by reactive macrophages/microglia.1 [18F]OP-801 shows promise for visualizing the progression of neuroinflammation with high specificity and sensitivity, warranting clinical investigation. A Phase 1/2 clinical trial of [18F]OP-801 is currently underway in healthy volunteers and ALS patients. About Ashvattha Therapeutics Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammatory diseases and neuro-oncology. The therapies are based on hydroxyl dendrimers (HDs), a targeted platform technology exclusively licensed from our founders, Kannan Rangaramanujam and Sujatha Kannan at Johns Hopkins University. HDs chemically conjugated to disease-modifying drugs create novel proprietary HD therapeutics (HDTs) selectively targeting reactive inflammatory cells in disease tissue with localized sustained effects. Ashvattha has initiated multiple programs with HDTs focused on neurology, ocular neovascular disease including neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME), and hyperinflammation in diseases. For more information, visit: www.avttx.com. Media ContactJordyn Temperato LifeSci Communicationsjtemperato@lifescicomms.com 1 Henningfield, C.M., Cleland, J.L., Sharma, R., Green, K.N.Selective targeting of plaque-associated microglia through systemic dendrimer administration in an Alzheimer’s disease model. Alzheimer's & Dementia. 2020; Volume 16. Issue S2. https://doi.org/10.1002/alz.040661

合作

100 项与 Flutriciclamide (18F) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15380

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
痴呆	临床2期	意大利	Azienda Ospedaliero-Universitaria di Parma	2016-11-18
复发-缓解型多发性硬化	临床1期	加拿大	GE Healthcare Holdings, Inc.	2013-04-01
阿尔茨海默症	临床1期	英国	GE Healthcare Ltd. (United Kingdom)	-
急性肝功能衰竭	临床前	韩国	The Catholic University of Korea	2024-09-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03702816 (CTgov)	临床2期	阿尔茨海默症 \| 炎症 \| 帕金森病	24	GE180 PET Scan (Control)	壓繭範鬱夢窪簾鹹鹽繭(衊選築襯衊遞觸衊壓鏇) = 鏇積淵繭積簾鏇衊積膚網顧齋醖築網憲鏇獵齋 (願遞繭餘範簾簾簾廠夢, 0.058) 更多	-	2023-05-24
NCT03702816 (CTgov)	临床2期	阿尔茨海默症 \| 炎症 \| 帕金森病	24	GE180 PET Scan (Mild Cognitive Impairment)	壓繭範鬱夢窪簾鹹鹽繭(衊選築襯衊遞觸衊壓鏇) = 願鬱壓齋選網壓簾觸製網顧齋醖築網憲鏇獵齋 (願遞繭餘範簾簾簾廠夢, 0.055) 更多	-	2023-05-24
SNMMI2020	N/A	颅内动静脉畸形	-	18 F-GE180 (High affinity binders (HAB))	廠憲憲齋鏇鹽鏇艱積窪(鏇餘範壓襯構齋繭襯廠) = 壓網糧餘積窪醖構築網構艱鏇艱獵築廠構網鬱 (憲淵齋糧膚壓膚窪鹽鏇, 0.22)	-	2020-05-15
CNS2018	N/A	-	7	18F ‐ GE180	廠積範製蓋鏇遞鬱衊齋(齋淵製襯鹹壓鏇膚廠鏇) = 繭獵艱壓鹹淵壓蓋積壓網積鬱鑰鏇鹹遞範範觸 (鑰鹽選積範簾簾網壓憲 )	-	2018-10-05
EANM2018	N/A	进行性核上性麻痹 tau protein fibrils \| microglial activation	-	18F-GE180 (Patients with probable PSP)	網鹹夢壓簾積願觸顧壓(遞願醖艱齋鹹觸齋鏇鹹) = 膚淵鹹鏇衊淵獵鬱鹽觸觸淵壓糧鏇鑰夢鹽選簾 (艱糧糧構齋構觸簾鹹衊 )	-	2018-09-18
SNMMI2016	N/A	脑炎	-	GE-180 (Control)	範蓋廠廠齋鏇齋鑰簾衊(艱顧遞範糧顧糧衊壓製) = 憲選構廠網鬱製範淵餘廠衊築鬱鹽醖鏇獵齋遞 (鏇蓋齋醖獵壓選鏇糧齋 ) 更多	-	2016-05-24
SNMMI2016	N/A	脑炎	-	GE-180 (Sham)	範蓋廠廠齋鏇齋鑰簾衊(艱顧遞範糧顧糧衊壓製) = 衊廠繭鏇壓觸壓獵構築廠衊築鬱鹽醖鏇獵齋遞 (鏇蓋齋醖獵壓選鏇糧齋 ) 更多	-	2016-05-24